Torrent First To Recall Drug Under New India Quality-Inspection Program
This article was originally published in PharmAsia News
India's Torrent Pharma has ordered a recall of two batches of its Ranitin (ranitidine) for treating acidity, after receiving a Central Drugs Standard Control Organisation notice the batches failed to meet quality standards.
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.